Lipid-Based Nanocarrier Systems for Drug Delivery: Advances and Applications

Yan-Qi Zhao; Li-Jun Li; Er-Fen Zhou; Jiang-Yue Wang; Ying Wang; Lin-Miao Guo; Xin-Xin Zhang

doi:10.1055/s-0042-1751036

Pharmaceutical Fronts, Table of Contents

CC BY 4.0 · Pharmaceutical Fronts 2022; 04(02): e43-e60
DOI: 10.1055/s-0042-1751036

Review Article

Lipid-Based Nanocarrier Systems for Drug Delivery: Advances and Applications

Yan-Qi Zhao

¹State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People's Republic of China

²University of Chinese Academy of Sciences, Beijing, People's Republic of China

,

Li-Jun Li

¹State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People's Republic of China

²University of Chinese Academy of Sciences, Beijing, People's Republic of China

,

Er-Fen Zhou

¹State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People's Republic of China

³School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, People's Republic of China

,

Jiang-Yue Wang

¹State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People's Republic of China

⁴School of Pharmacy, East China University of Science and Technology, Shanghai, People's Republic of China

,

Ying Wang

¹State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People's Republic of China

²University of Chinese Academy of Sciences, Beijing, People's Republic of China

,

Lin-Miao Guo

¹State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People's Republic of China

²University of Chinese Academy of Sciences, Beijing, People's Republic of China

,

Xin-Xin Zhang

¹State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People's Republic of China

²University of Chinese Academy of Sciences, Beijing, People's Republic of China

› Author Affiliations

Abstract

Lipid-based nanocarriers have been extensively investigated for drug delivery due to their advantages including biodegradability, biocompatibility, nontoxicity, and nonimmunogenicity. However, the shortcomings of traditional lipid-based nanocarriers such as insufficient targeting, capture by the reticuloendothelial system, and fast elimination limit the efficiency of drug delivery and therapeutic efficacy. Therefore, a series of multifunctional lipid-based nanocarriers have been developed to enhance the accumulation of drugs in the lesion site, aiming for improved diagnosis and treatment of various diseases. In this review, we summarized the advances and applications of lipid-based nanocarriers from traditional to novel functional lipid preparations, including liposomes, stimuli-responsive lipid-based nanocarriers, ionizable lipid nanoparticles, lipid hybrid nanocarriers, as well as biomembrane-camouflaged nanoparticles, and further discussed the challenges and prospects of this system. This exploration may give a complete idea viewing the lipid-based nanocarriers as a promising choice for drug delivery system, and fuel the advancement of pharmaceutical products by materials innovation and nanotechnology.

Keywords

lipid-based nanocarriers - drug delivery - nanomedicine - lipid materials - clinical application

Full Text

References

References
1 Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004; 303 (5665): 1818-1822
2 Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 2021; 20 (02) 101-124
3 Zafar H, Raza F, Ma S, Wei Y, Zhang J, Shen Q. Recent progress on nanomedicine-induced ferroptosis for cancer therapy. Biomater Sci 2021; 9 (15) 5092-5115
4 Zhang Y, Chan HF, Leong KW. Advanced materials and processing for drug delivery: the past and the future. Adv Drug Deliv Rev 2013; 65 (01) 104-120
5 Doktorovova S, Souto EB, Silva AM. Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers - a systematic review of in vitro data. Eur J Pharm Biopharm 2014; 87 (01) 1-18
6 Khan I, Saeed K, Khan I. Nanoparticles: properties, applications and toxicities. Arab J Chem 2019; 12 (07) 908-931
7 Agrawal M, Saraf S, Saraf S. et al. Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting. J Control Release 2020; 321: 372-415
8 Chakravarty M, Vora A. Nanotechnology-based antiviral therapeutics. Drug Deliv Transl Res 2021; 11 (03) 748-787
9 Xing H, Hwang K, Lu Y. Recent developments of liposomes as nanocarriers for theranostic applications. Theranostics 2016; 6 (09) 1336-1352
10 Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4 (02) 145-160
11 Alving CR, Beck Z, Karasavva N, Matyas GR, Rao M. HIV-1, lipid rafts, and antibodies to liposomes: implications for anti-viral-neutralizing antibodies. Mol Membr Biol 2006; 23 (06) 453-465
12 Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater 2021; 6 (12) 1078-1094
13 Ando H, Ishida T. An RNAi therapeutic, DFP-10825, for intraperitoneal and intrapleural malignant cancers. Adv Drug Deliv Rev 2020; 154–155: 27-36
14 Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev 2014; 66: 110-116
15 Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol 1964; 8: 660-668
16 Zakaria S, Gamal-Eldeen AM, El-Daly SM, Saleh S. Synergistic apoptotic effect of Doxil ® and aminolevulinic acid-based photodynamic therapy on human breast adenocarcinoma cells. Photodiagn Photodyn Ther 2014; 11 (02) 227-238
17 Porche DJ. Liposomal doxorubicin (Doxil). J Assoc Nurses AIDS Care 1996; 7 (02) 55-59
18 Phuphanich S, Maria B, Braeckman R, Chamberlain M. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol 2007; 81 (02) 201-208
19 Passero Jr FC, Grapsa D, Syrigos KN, Saif MW. The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy. Expert Rev Anticancer Ther 2016; 16 (07) 697-703
20 Lamb YN, Scott LJ. Liposomal irinotecan: a review in metastatic pancreatic adenocarcinoma. Drugs 2017; 77 (07) 785-792
21 Frampton JE. Liposomal irinotecan: a review in metastatic pancreatic adenocarcinoma. Drugs 2020; 80 (10) 1007-1018
22 Lambrechts M, O'Brien MJ, Savoie FH, You Z. Liposomal extended-release bupivacaine for postsurgical analgesia. Patient Prefer Adherence 2013; 7: 885-890
23 Kaye AD, Armstead-Williams C, Hyatali F. et al. Exparel for postoperative pain management: a comprehensive review. Curr Pain Headache Rep 2020; 24 (11) 73
24 Hu D, Onel E, Singla N, Kramer WG, Hadzic A. Pharmacokinetic profile of liposome bupivacaine injection following a single administration at the surgical site. Clin Drug Investig 2013; 33 (02) 109-115
25 Tong YC, Kaye AD, Urman RD. Liposomal bupivacaine and clinical outcomes. Best Pract Res Clin Anaesthesiol 2014; 28 (01) 15-27
26 Onishchenko N, Tretiakova D, Vodovozova E. Spotlight on the protein corona of liposomes. Acta Biomater 2021; 134: 57-78
27 Kierstead PH, Okochi H, Venditto VJ. et al. The effect of polymer backbone chemistry on the induction of the accelerated blood clearance in polymer modified liposomes. J Control Release 2015; 213: 1-9
28 Fernandes DA, Fernandes DD, Gradinaru CC, Kolios MC. In vitro studies of multifunctional perfluorocarbon nanoemulsions for cancer therapy and imaging. Biophys J 2016; 110 (3, Suppl 1): 503A
29 Gang C, Kaikai W, Pengkai W. et al. Development of fluorinated polyplex nanoemulsions for improved small interfering RNA delivery and cancer therapy. Nano Res 2018; 11: 3746-3761
30 Gupta A, Eral HB, Hatton TA, Doyle PS. Nanoemulsions: formation, properties and applications. Soft Matter 2016; 12 (11) 2826-2841
31 Sahu P, Das D, Mishra VK, Kashaw V, Kashaw SK. Nanoemulsion: a novel eon in cancer chemotherapy. Mini Rev Med Chem 2017; 17 (18) 1778-1792
32 Choudhury H, Gorain B, Chatterjee B, Mandal UK, Sengupta P, Tekade RK. Pharmacokinetic and pharmacodynamic features of nanoemulsion following oral, intravenous, topical and nasal route. Curr Pharm Des 2017; 23 (17) 2504-2531
33 Thompson KA, Goodale DB. The recent development of propofol (DIPRIVAN). Intensive Care Med 2000; 26 (Suppl. 04) S400-S404
34 Baker MT, Naguib M. Propofol: the challenges of formulation. Anesthesiology 2005; 103 (04) 860-876
35 Lee EH, Lee SH, Park DY. et al. Physicochemical properties, pharmacokinetics, and pharmacodynamics of a reformulated microemulsion propofol in rats. Anesthesiology 2008; 109 (03) 436-447
36 Navari RM, Mosier MC. Crossover safety study of aprepitant: 2-min injection vs 30-min infusion in cancer patients receiving emetogenic chemotherapy. OncoTargets Ther 2019; 12: 3277-3284
37 Ottoboni T, Lauw M, Keller MR. et al. HTX-019 via 2-min injection or 30-min infusion in healthy subjects. Future Oncol 2019; 15 (08) 865-874
38 Navari RM. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review. Expert Opin Drug Saf 2020; 19 (02) 205-210
39 Bose A, Roy Burman D, Sikdar B, Patra P. Nanomicelles: types, properties and applications in drug delivery. IET Nanobiotechnol 2021; 15 (01) 19-27
40 Ma M, Hao Y, Liu N. et al. A novel lipid-based nanomicelle of docetaxel: evaluation of antitumor activity and biodistribution. Int J Nanomedicine 2012; 7: 3389-3398
41 Musacchio T, Torchilin VP. Recent developments in lipid-based pharmaceutical nanocarriers. Front Biosci 2011; 16 (04) 1388-1412
42 Bahadori F, Topçu G, Eroğlu MS, Onyüksel H. A new lipid-based nano formulation of vinorelbine. AAPS PharmSciTech 2014; 15 (05) 1138-1148
43 Onyüksel H, Jeon E, Rubinstein I. Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells. Cancer Lett 2009; 274 (02) 327-330
44 Dagar A, Kuzmis A, Rubinstein I, Sekosan M, Onyuksel H. VIP-targeted cytotoxic nanomedicine for breast cancer. Drug Deliv Transl Res 2012; 2 (06) 454-462
45 Onyüksel H, Mohanty PS, Rubinstein I. VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer. Int J Pharm 2009; 365 (1–2): 157-161
46 Aquib M, Farooq MA, Banerjee P. et al. Targeted and stimuli-responsive mesoporous silica nanoparticles for drug delivery and theranostic use. J Biomed Mater Res A 2019; 107 (12) 2643-2666
47 Liu J, Huang Y, Kumar A. et al. pH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol Adv 2014; 32 (04) 693-710
48 Jin Y, Song L, Su Y. et al. Oxime linkage: a robust tool for the design of pH-sensitive polymeric drug carriers. Biomacromolecules 2011; 12 (10) 3460-3468
49 Pafiti K, Cui Z, Adlam D, Hoyland J, Freemont AJ, Saunders BR. Hydrogel Composites containing sacrificial collapsed hollow particles as dual action pH-responsive biomaterials. Biomacromolecules 2016; 17 (07) 2448-2458
50 Du Y, Chen W, Zheng M, Meng F, Zhong Z. pH-sensitive degradable chimaeric polymersomes for the intracellular release of doxorubicin hydrochloride. Biomaterials 2012; 33 (29) 7291-7299
51 Du JZ, Du XJ, Mao CQ, Wang J. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. J Am Chem Soc 2011; 133 (44) 17560-17563
52 Ren D, Kratz F, Wang SW. Protein nanocapsules containing doxorubicin as a pH-responsive delivery system. Small 2011; 7 (08) 1051-1060
53 Kanamala M, Wilson WR, Yang M, Palmer BD, Wu Z. Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: a review. Biomaterials 2016; 85: 152-167
54 Lee JM, Park H, Oh KT, Lee ES. pH-Responsive hyaluronated liposomes for docetaxel delivery. Int J Pharm 2018; 547 (1–2): 377-384
55 Soares DC, de Oliveira MC, dos Santos RG. et al. Liposomes radiolabeled with 159Gd-DTPA-BMA: preparation, physicochemical characterization, release profile and in vitro cytotoxic evaluation. Eur J Pharm Sci 2011; 42 (05) 462-469
56 Li N, Cai H, Jiang L. et al. Enzyme-sensitive and amphiphilic PEGylated dendrimer-paclitaxel prodrug-based nanoparticles for enhanced stability and anticancer efficacy. ACS Appl Mater Interfaces 2017; 9 (08) 6865-6877
57 Zhu L, Torchilin VP. Stimulus-responsive nanopreparations for tumor targeting. Integr Biol 2013; 5 (01) 96-107
58 Fleige E, Quadir MA, Haag R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. Adv Drug Deliv Rev 2012; 64 (09) 866-884
59 Chen M, Miao Y, Qian K. et al. Detachable liposomes combined immunochemotherapy for enhanced triple-negative breast cancer treatment through reprogramming of tumor-associated macrophages. Nano Lett 2021; 21 (14) 6031-6041
60 Lee S, Song SJ, Lee J, Ha TH, Choi JS. Cathepsin B-responsive liposomes for controlled anticancer drug delivery in Hep G2 cells. Pharmaceutics 2020; 12 (09) 876
61 Ji T, Li S, Zhang Y. et al. An MMP-2 responsive liposome integrating antifibrosis and chemotherapeutic drugs for enhanced drug perfusion and efficacy in pancreatic cancer. ACS Appl Mater Interfaces 2016; 8 (05) 3438-3445
62 Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov 2014; 13 (11) 813-827
63 Candiani G, Pezzoli D, Ciani L, Chiesa R, Ristori S. Bioreducible liposomes for gene delivery: from the formulation to the mechanism of action. PLoS One 2010; 5 (10) e13430
64 Liu J, Pang Y, Huang W. et al. Redox-responsive polyphosphate nanosized assemblies: a smart drug delivery platform for cancer therapy. Biomacromolecules 2011; 12 (06) 2407-2415
65 Fu H, Shi K, Hu G. et al. Tumor-targeted paclitaxel delivery and enhanced penetration using TAT-decorated liposomes comprising redox-responsive poly(ethylene glycol). J Pharm Sci 2015; 104 (03) 1160-1173
66 Anguela XM, High KA. Entering the modern era of gene therapy. Annu Rev Med 2019; 70: 273-288
67 Schlich M, Palomba R, Costabile G. et al. Cytosolic delivery of nucleic acids: the case of ionizable lipid nanoparticles. Bioeng Transl Med 2021; 6 (02) e10213
68 Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009; 8 (02) 129-138
69 Pilkington EH, Suys EJA, Trevaskis NL. et al. From influenza to COVID-19: lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. Acta Biomater 2021; 131: 16-40
70 Mukai H, Ogawa K, Kato N, Kawakami S. Recent advances in lipid nanoparticles for delivery of nucleic acid, mRNA, and gene editing-based therapeutics. Drug Metab Pharmacokinet 2022; 44: 100450
71 Samaridou E, Heyes J, Lutwyche P. Lipid nanoparticles for nucleic acid delivery: current perspectives. Adv Drug Deliv Rev 2020; 154–155: 37-63
72 Saw PE, Song EW. siRNA therapeutics: a clinical reality. Sci China Life Sci 2020; 63 (04) 485-500
73 Ross-Thriepland D, Bornot A, Butler L. et al. Arrayed CRISPR screening identifies novel targets that enhance the productive delivery of mRNA by MC3-based lipid nanoparticles. SLAS Discov 2020; 25 (06) 605-617
74 Han X, Zhang H, Butowska K. et al. An ionizable lipid toolbox for RNA delivery. Nat Commun 2021; 12 (01) 7233
75 Lamb YN. BNT162b2 mRNA COVID-19 vaccine: first approval. Drugs 2021; 81 (04) 495-501
76 Candela M, Luconi V, Vecchio A. Impact of the COVID-19 pandemic on the Internet latency: a large-scale study. Comput Netw 2020; 182: 107495
77 Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov 2021; 20 (11) 817-838
78 Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov 2018; 17 (04) 261-279
79 Dhaliwal HK, Fan Y, Kim J, Amiji MM. Intranasal delivery and transfection of mRNA therapeutics in the brain using cationic liposomes. Mol Pharm 2020; 17 (06) 1996-2005
80 He S, Fan W, Wu N. et al. Lipid-based liquid crystalline nanoparticles facilitate cytosolic delivery of siRNA via structural transformation. Nano Lett 2018; 18 (04) 2411-2419
81 Rosenblum D, Gutkin A, Kedmi R. et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci Adv 2020; 6 (47) eabc9450
82 Dahlman JE, Barnes C, Khan O. et al. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat Nanotechnol 2014; 9 (08) 648-655
83 Lin YX, Wang Y, Ding J. et al. Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models. Sci Transl Med 2021; 13 (599) eaba9772
84 Maier MA, Jayaraman M, Matsuda S. et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther 2013; 21 (08) 1570-1578
85 Zhang HW. A bright future for lipid nanoparticles in gene therapy. Cell Gene Ther Insights 2021; 7 (06) 755-758
86 Jayaraman M, Ansell SM, Mui BL. et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl 2012; 51 (34) 8529-8533
87 Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol 1995; 13 (12) 527-537
88 Lee SM, Ahn RW, Chen F. et al. Biological evaluation of pH-responsive polymer-caged nanobins for breast cancer therapy. ACS Nano 2010; 4 (09) 4971-4978
89 Lee SM, Chen H, Dettmer CM, O'Halloran TV, Nguyen ST. Polymer-caged lipsomes: a pH-responsive delivery system with high stability. J Am Chem Soc 2007; 129 (49) 15096-15097
90 Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F, Nanoencapsulation I. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine (Lond) 2006; 2 (01) 8-21
91 Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007; 2 (12) 751-760
92 Hokmabad VR, Davaran S, Aghazadeh M, Alizadeh E, Salehi R, Ramazani A. A comparison of the effects of silica and hydroxyapatite nanoparticles on poly(ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone)/chitosan nanofibrous scaffolds for bone tissue engineering. Tissue Eng Regen Med 2018; 15 (06) 735-750
93 Raza F, Zafar H, You X, Khan A, Wu J, Ge L. Cancer nanomedicine: focus on recent developments and self-assembled peptide nanocarriers. J Mater Chem B Mater Biol Med 2019; 7 (48) 7639-7655
94 Asthana S, Jaiswal AK, Gupta PK, Dube A, Chourasia MK. Th-1 biased immunomodulation and synergistic antileishmanial activity of stable cationic lipid-polymer hybrid nanoparticle: biodistribution and toxicity assessment of encapsulated amphotericin B. Eur J Pharm Biopharm 2015; 89: 62-73
95 Yang P, Zhang L, Wang T. et al. Doxorubicin and edelfosine combo-loaded lipid-polymer hybrid nanoparticles for synergistic anticancer effect against drug-resistant osteosarcoma. OncoTargets Ther 2020; 13: 8055-8067
96 Li J, Xu W, Yuan X. et al. Polymer-lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells. Int J Nanomedicine 2017; 12: 6909-6921
97 He Z, Zhang Y, Feng N. Cell membrane-coated nanosized active targeted drug delivery systems homing to tumor cells: a review. Mater Sci Eng C 2020; 106: 110298
98 Song Y, Huang Z, Liu X. et al. Platelet membrane-coated nanoparticle-mediated targeting delivery of Rapamycin blocks atherosclerotic plaque development and stabilizes plaque in apolipoprotein E-deficient (ApoE^-/-) mice. Nanomedicine (Lond) 2019; 15 (01) 13-24
99 Zhang Q, Dehaini D, Zhang Y. et al. Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis. Nat Nanotechnol 2018; 13 (12) 1182-1190
100 Pitchaimani A, Nguyen TDT, Aryal S. Natural killer cell membrane infused biomimetic liposomes for targeted tumor therapy. Biomaterials 2018; 160: 124-137
101 Zhou X, Miao Y, Wang Y. et al. Tumour-derived extracellular vesicle membrane hybrid lipid nanovesicles enhance siRNA delivery by tumour-homing and intracellular freeway transportation. J Extracell Vesicles 2022; 11 (03) e12198
102 Miao Y, Yang Y, Guo L. et al. Cell membrane-camouflaged nanocarriers with biomimetic deformability of erythrocytes for ultralong circulation and enhanced cancer therapy. ACS Nano 2022; 16 (04) 6527-6540
103 Müller RH, Shegokar R, Keck CM. 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr Drug Discov Technol 2011; 8 (03) 207-227
104 Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000; 50 (01) 161-177
105 Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J. Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target 2012; 20 (10) 813-830
106 Musielak E, Feliczak-Guzik A, Nowak I. Synthesis and potential applications of lipid nanoparticles in medicine. Materials (Basel) 2022; 15 (02) 682
107 Souto EB, Almeida AJ, Müller RH. Lipid nanoparticles (SLN^®, NLC^®) for cutaneous drug delivery:structure, protection and skin effects. J Biomed Nanotechnol 2007; 3 (04) 317-331
108 Thi TTH, Suys EJA, Lee JS, Nguyen DH, Park KD, Truong NP. Lipid-based nanoparticles in the clinic and clinical trials: from cancer nanomedicine to COVID-19 vaccines. Vaccines (Basel) 2021; 9 (04) 359
109 Azhar Shekoufeh Bahari L, Hamishehkar H. The impact of variables on particle size of solid lipid nanoparticles and nanostructured lipid carriers; a comparative literature review. Adv Pharm Bull 2016; 6 (02) 143-151
110 Silva CO, Pinho JO, Lopes JM, Almeida AJ, Gaspar MM, Reis C. Current trends in cancer nanotheranostics: metallic, polymeric, and lipid-based systems. Pharmaceutics 2019; 11 (01) 22
111 Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011; 12 (01) 62-76
112 Muchow M, Maincent P, Muller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm 2008; 34 (12) 1394-1405
113 Talegaonkar S, Bhattacharyya A. Potential of lipid nanoparticles (SLNs and NLCs) in enhancing oral bioavailability of drugs with poor intestinal permeability. AAPS PharmSciTech 2019; 20 (03) 121
114 Dumont C, Bourgeois S, Fessi H, Jannin V. Lipid-based nanosuspensions for oral delivery of peptides, a critical review. Int J Pharm 2018; 541 (1–2): 117-135
115 Puglia C, Offerta A, Carbone C, Bonina F, Pignatello R, Puglisi G. Lipid nanocarriers (LNC) and their applications in ocular drug delivery. Curr Med Chem 2015; 22 (13) 1589-1602
116 Sguizzato M, Esposito E, Cortesi R. Lipid-based nanosystems as a tool to overcome skin barrier. Int J Mol Sci 2021; 22 (15) 8319
117 Araujo VHS, Delello Di Filippo L, Duarte JL. et al. Exploiting solid lipid nanoparticles and nanostructured lipid carriers for drug delivery against cutaneous fungal infections. Crit Rev Microbiol 2021; 47 (01) 79-90
118 Lauterbach A, Müller-Goymann CC. Applications and limitations of lipid nanoparticles in dermal and transdermal drug delivery via the follicular route. Eur J Pharm Biopharm 2015; 97 (Pt A): 152-163
119 Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004; 56 (09) 1257-1272
120 de Oliveira IF, Barbosa EJ, Peters MCC. et al. Cutting-edge advances in therapy for the posterior segment of the eye: solid lipid nanoparticles and nanostructured lipid carriers. Int J Pharm 2020; 589: 119831
121 Suresh PK, Sah AK. Patent perspectives for corticosteroids based ophthalmic therapeutics. Recent Pat Drug Deliv Formul 2014; 8 (03) 206-223
122 Weber S, Zimmer A, Pardeike J. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art. Eur J Pharm Biopharm 2014; 86 (01) 7-22
123 Costa CP, Moreira JN, Sousa Lobo JM, Silva AC. Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: a current overview of in vivo studies. Acta Pharm Sin B 2021; 11 (04) 925-940
124 Costa CP, Barreiro S, Moreira JN. et al. In vitro studies on nasal formulations of nanostructured lipid carriers (NLC) and solid lipid nanoparticles (SLN). Pharmaceuticals (Basel) 2021; 14 (08) 711
125 Teixeira MI, Lopes CM, Amaral MH, Costa PC. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases. Eur J Pharm Biopharm 2020; 149: 192-217
126 Agrawal M, Saraf S, Saraf S. et al. Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region. Expert Opin Drug Deliv 2018; 15 (06) 589-617
127 Stefanov SR, Andonova VY. Lipid nanoparticulate drug delivery systems: recent advances in the treatment of skin disorders. Pharmaceuticals (Basel) 2021; 14 (11) 1083
128 Mahmoud RA, Hussein AK, Nasef GA, Mansour HF. Oxiconazole nitrate solid lipid nanoparticles: formulation, in-vitro characterization and clinical assessment of an analogous loaded carbopol gel. Drug Dev Ind Pharm 2020; 46 (05) 706-716
129 Balguri SP, Adelli GR, Majumdar S. Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues. Eur J Pharm Biopharm 2016; 109: 224-235
130 Dobreva M, Stefanov S, Andonova V. Natural lipids as structural components of solid lipid nanoparticles and nanostructured lipid carriers for topical delivery. Curr Pharm Des 2020; 26 (36) 4524-4535
131 Scioli Montoto S, Muraca G, Ruiz ME. Solid lipid nanoparticles for drug delivery: pharmacological and biopharmaceutical aspects. Front Mol Biosci 2020; 7: 587997
132 Garcês A, Amaral MH, Sousa Lobo JM, Silva AC. Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: a review. Eur J Pharm Sci 2018; 112: 159-167
133 Huang HC, Barua S, Sharma G, Dey SK, Rege K. Inorganic nanoparticles for cancer imaging and therapy. J Control Release 2011; 155 (03) 344-357
134 Soundharraj P, Dhinasekaran D, Aruna P, Ganesan S. Facile synthesis of biomass silica-silver colloidal nanoparticles and its application as highly sensitive fluorescent biosensor. Surf Interfaces 2021; 23: 101010
135 Loh XJ, Lee TC, Dou Q, Deen GR. Utilising inorganic nanocarriers for gene delivery. Biomater Sci 2016; 4 (01) 70-86
136 Lombardo D, Kiselev MA, Caccamo MT. Smart nanoparticles for drug delivery application: development of versatile nanocarrier platforms in biotechnology and nanomedicine. J Nanomater 2019; 2019: 1-26
137 Carvalho BG, Ceccato BT, Michelon M, Han SW, de la Torre LG. Advanced microfluidic technologies for lipid nano-microsystems from synthesis to biological application. Pharmaceutics 2022; 14 (01) 141
138 Bukhari SI, Imam SS, Ahmad MZ. et al. Recent progress in lipid nanoparticles for cancer theranostics: opportunity and challenges. Pharmaceutics 2021; 13 (06) 840
139 Esim O, Hascicek C. Lipid-coated nanosized drug delivery systems for an effective cancer therapy. Curr Drug Deliv 2021; 18 (02) 147-161
140 Kong WH, Bae KH, Jo SD, Kim JS, Park TG. Cationic lipid-coated gold nanoparticles as efficient and non-cytotoxic intracellular siRNA delivery vehicles. Pharm Res 2012; 29 (02) 362-374
141 Liu W, He Z, Liang JG, Zhu YL, Xu HB, Yang XL. Preparation and characterization of novel fluorescent nanocomposite particles: CdSe/ZnS core-shell quantum dots loaded solid lipid nanoparticles. J Biomed Mater Res A 2008; 84 (04) 1018-1025
142 Khan MW, Zhao P, Khan A. et al. Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity. Int J Nanomedicine 2019; 14: 3753-3771
143 Chatterjee K, Sarkar S, Jagajjanani Rao K, Paria S. Core/shell nanoparticles in biomedical applications. Adv Colloid Interface Sci 2014; 209: 8-39
144 Chan HK, Kwok PCL. Production methods for nanodrug particles using the bottom-up approach. Adv Drug Deliv Rev 2011; 63 (06) 406-416
145 Pellegrino J, Schulte LR, De la Cruz J, Stoldt C. Membrane processes in nanoparticle production. J Membr Sci 2017; 522: 245-256
146 Toh M-R, Chiu GNC. Liposomes as sterile preparations and limitations of sterilisation techniques in liposomal manufacturing. Asian J Pharm Sci 2013; 8 (02) 88-95
147 Yu JY, Chuesiang P, Shin GH, Park HJ. Post-processing techniques for the improvement of liposome stability. Pharmaceutics 2021; 13 (07) 1023
148 Álvarez-Benedicto E, Farbiak L, Márquez Ramírez M. et al. Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA). Biomater Sci 2022; 10 (02) 549-559
149 Chang C, Meikle TG, Drummond CJ, Yang Y, Conn CE. Comparison of cubosomes and liposomes for the encapsulation and delivery of curcumin. Soft Matter 2021; 17 (12) 3306-3313
150 Milane L, Amiji M. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine. Drug Deliv Transl Res 2021; 11 (04) 1309-1315
151 Barenholz Y. Doxil®–the first FDA-approved nano-drug: lessons learned. J Control Release 2012; 160 (02) 117-134
152 Wood LS. Liposomal anthracycline administration and toxicity management: a nursing perspective. Semin Oncol 2004; 31 (6, Suppl 13): 182-190
153 Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs 2013; 73 (09) 919-934
154 Kim L, Glantz MJ. Neoplastic meningitis. Curr Treat Options Oncol 2001; 2 (06) 517-527
155 Glück S, Chadderton A, Ho AD. The selective uptake of benzoporphyrin derivative mono-acid ring A results in differential cell kill of multiple myeloma cells in vitro. Photochem Photobiol 1996; 63 (06) 846-853
156 Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int (Roma) 2018; 60 (01) 4-12
157 de Man FM, Goey AKL, van Schaik RHN, Mathijssen RHJ, Bins S. Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet 2018; 57 (10) 1229-1254
158 Kantarjian HM, Kadia TM, DiNardo CD, Welch MA, Ravandi F. Acute myeloid leukemia: treatment and research outlook for 2021 and the MD Anderson approach. Cancer 2021; 127 (08) 1186-1207
159 Suresh G, Manjunath K, Venkateswarlu V, Satyanarayana V. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech 2007; 8 (01) 24
160 Shegokar R, Singh KK, Müller RH. Production & stability of stavudine solid lipid nanoparticles–from lab to industrial scale. Int J Pharm 2011; 416 (02) 461-470
161 Möschwitzer JP. Drug nanocrystals in the commercial pharmaceutical development process. Int J Pharm 2013; 453 (01) 142-156
162 Loh ZH, Samanta AK, Sia Heng PW. Overview of milling techniques for improving the solubility of poorly water-soluble drugs. Asian J Pharm Sci 2015; 10 (04) 255-274
163 Kamiya S, Yamada M, Kurita T, Miyagishima A, Arakawa M, Sonobe T. Preparation and stabilization of nifedipine lipid nanoparticles. Int J Pharm 2008; 354 (1–2): 242-247
164 Buse J, El-Aneed A. Properties, engineering and applications of lipid-based nanoparticle drug-delivery systems: current research and advances. Nanomedicine (Lond) 2010; 5 (08) 1237-1260
165 Wang J, He W, Cheng L. et al. A modified thin film method for large scale production of dimeric artesunate phospholipid liposomes and comparison with conventional approaches. Int J Pharm 2022; 619: 121714
166 Sugikawa K, Kadota T, Yasuhara K, Ikeda A. Anisotropic self-assembly of citrate-coated gold nanoparticles on fluidic liposomes. Angew Chem Int Ed Engl 2016; 55 (12) 4059-4063
167 Shen Z, Loe DT, Fisher A, Kröger M, Rouge JL, Li Y. Polymer stiffness governs template mediated self-assembly of liposome-like nanoparticles: simulation, theory and experiment. Nanoscale 2019; 11 (42) 20179-20193
168 Sheshachala S, Grösche M, Scherr T. et al. Segregation of dispersed silica nanoparticles in microfluidic water-in-oil droplets: a kinetic study. ChemPhysChem 2020; 21 (10) 1070-1078
169 Dutta K, Bochicchio D, Ribbe AE. et al. Symbiotic self-assembly strategy toward lipid-encased cross-linked polymer nanoparticles for efficient gene silencing. ACS Appl Mater Interfaces 2019; 11 (28) 24971-24983
170 Xia HM, Seah YP, Liu YC, Wang W, Toh AGG, Wang ZP. Anti-solvent precipitation of solid lipid nanoparticles using a microfluidic oscillator mixer. Microfluid Nanofluidics 2015; 19 (02) 283-290
171 Liu Y, Salituro GM, Lee KJ, Bak A, Leung DH. Modulating drug release and enhancing the oral bioavailability of torcetrapib with solid lipid dispersion formulations. AAPS PharmSciTech 2015; 16 (05) 1091-1100
172 Battaglia L, Gallarate M, Cavalli R, Trotta M. Solid lipid nanoparticles produced through a coacervation method. J Microencapsul 2010; 27 (01) 78-85
173 Liu D, Jiang S, Shen H. et al. Diclofenac sodium-loaded solid lipid nanoparticles prepared by emulsion/solvent evaporation method. J Nanopart Res 2011; 13 (06) 2375-2386
174 Kumar R. Nanotechnology based approaches to enhance aqueous solubility and bioavailability of griseofulvin: a literature survey. J Drug Deliv Sci Technol 2019; 53: 101221
175 Kim DH, Lim S, Shim J. et al. A simple evaporation method for large-scale production of liquid crystalline lipid nanoparticles with various internal structures. ACS Appl Mater Interfaces 2015; 7 (36) 20438-20446
176 Wang L, Griffel B, Xu X. Synthesis of PLGA-lipid hybrid nanoparticles for siRNA delivery using the emulsion method PLGA-PEG-lipid nanoparticles for siRNA delivery. Methods Mol Biol 2017; 1632: 231-240
177 Maeki M, Uno S, Niwa A, Okada Y, Tokeshi M. Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery. J Control Release 2022; 344: 80-96
178 Maeki M, Kimura N, Sato Y, Harashima H, Tokeshi M. Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems. Adv Drug Deliv Rev 2018; 128: 84-100
179 Zhang B, Zhou X, Miao Y. et al. Effect of phosphatidylcholine on the stability and lipolysis of nanoemulsion drug delivery systems. Int J Pharm 2020; 583: 119354
180 Zhu C, Gong S, Ding J. et al. Supersaturated polymeric micelles for oral silybin delivery: the role of the Soluplus-PVPVA complex. Acta Pharm Sin B 2019; 9 (01) 107-117
181 Yu M, Xu L, Tian F. et al. Rapid transport of deformation-tuned nanoparticles across biological hydrogels and cellular barriers. Nat Commun 2018; 9 (01) 2607
182 Zhang X, Angsantikul P, Ying M. et al. Remote loading of small-molecule therapeutics into cholesterol-enriched cell membrane-derived vesicles. Angew Chem Int Ed Engl 2017; 56 (45) 14075-14079
183 Ying M, Zhuang J, Wei X. et al. Remote-loaded platelet vesicles for disease-targeted delivery of therapeutics. Adv Funct Mater 2018; 28 (22) 1801032
184 Nie D, Dai Z, Li J. et al. Cancer-cell-membrane-coated nanoparticles with a yolk-shell structure augment cancer chemotherapy. Nano Lett 2020; 20 (02) 936-946
185 Guihong C, Yufang M, Shaoqing C, Fuqiang H, Yong G, Hong Y. Transport features and structural optimization of solid lipid nanoparticles crossing the intestinal epithelium. RSC Advances 2016; 6 (74) 70433-70445
186 Liang J, Zhang X, Miao Y, Li J, Gan Y. Lipid-coated iron oxide nanoparticles for dual-modal imaging of hepatocellular carcinoma. Int J Nanomedicine 2017; 12: 2033-2044